Loading…
Employees: 1,256
Size Boji Medical Technology (300404.SZ) is a China Health Care company (Biotechnology) with a market value of $664M, the 3190th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.48 on 6 Nov 2026.
Performance Over six months the shares gained 6.9%, against -22.0% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 31.9% over the last twelve months (peer median +18.6%); the operating margin is 3.7% (peer median -135.1%).
Valuation It trades at 82.0× forward earnings against a peer median of 23.0× (most expensive of 5).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.6 points below its cost of capital (7.9% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.02B | CN¥865M | CN¥739M | CN¥554M | CN¥422M |
| Revenue growth | — | +17% | +33% | +31% | — |
| Gross profit | CN¥257M | CN¥212M | CN¥204M | CN¥166M | CN¥145M |
| EBITDA | n/a | CN¥52.3M | CN¥38.5M | CN¥25.0M | CN¥29.9M |
| Net income | CN¥57.9M | CN¥30.5M | CN¥28.8M | CN¥24.3M | CN¥27.7M |
| Free cash flow | CN¥55.1M | CN¥70.5M | CN¥448,420 | -CN¥23.6M | -CN¥86.2M |
| Capital expenditure | CN¥21.2M | CN¥18.7M | CN¥29.4M | CN¥62.2M | CN¥118M |
| Total debt | CN¥43.2M | CN¥46.4M | CN¥49.9M | CN¥116M | CN¥80.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300404.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.5% | -9.7% | 5th lowest of 21 |
| 6-month return | +6.9% | -22.0% | 4th highest of 19 |
| Distance from 52-week high | -36.2% | -44.7% | 6th highest of 21 |
| Revenue growth (TTM) | +31.9% | +18.6% | 6th highest of 14 |
| Operating margin | 3.7% | -135.1% | 3rd highest of 15 |
| Forward P/E | 82.0× | 23.0× | most expensive of 5 |
| Growth the price implies (Req g, 7 yrs) | 35.4% | 40.0% | 2nd least demanding of 4 |
| Growth delivered (Del g) | +27.2% | +21.5% | 2nd highest of 4 |
| Hurdle (Req g minus delivered) | +8.2 pp | -7.0 pp | 2nd most demanding of 4 |
| ROIC minus cost of capital | -2.6 pp | -49.1 pp | 4th highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 82.0× | 35.4% | +27.2% |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | n/a | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | n/a | -8.3% | -1.3% |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 20.7× | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 25.4× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 16.7× | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | n/a | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 79.3× | 40.0% | +143.5% |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | n/a | 43.2% | +21.5% |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | n/a | n/a | n/a |